Revised Maximum Retail Prices (MRPs) of 1,364 anti-cancer medicine formulations came into effect across India on November 9, 2026, following a government decision to cap trade margins on selected cancer medicines.
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has capped trade margins on the MRPs of 137 anti-cancer drugs. The move follows recommendations made by an expert committee constituted by the Directorate General of Health Services on October 17, 2026.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: Revised MRPs of 1,364 anti-cancer medicine formulations came into effect.
Location: India.
Authority/Organisation: National Pharmaceutical Pricing Authority and Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Action Taken: Trade margins on the MRPs of 137 anti-cancer drugs were capped under the government's pricing intervention.
- Impact: The government estimates annual consumer savings of ₹3,540.38 crore, potentially improving affordability of cancer medicines.
According to the government, 85 pharmaceutical companies had reported revised MRPs for 1,364 formulations covering 121 drugs as of November 8. Among these, 679 brands reported price reductions exceeding 50 per cent. The highest reported reduction in MRP was 96.45 per cent.
The government estimates that the revised prices could generate annual savings of approximately ₹3,540.38 crore for consumers. This figure is a projected annual saving, not an amount already received by patients.
The revised prices are intended to improve affordability and reduce the financial burden associated with cancer treatment. Medicines can represent a significant component of treatment expenses, particularly for patients requiring long-term medication.
Editorial Analysis
Why This Matters
Cancer treatment can place a substantial financial burden on patients and their families. Reducing the prices of essential medicines can improve affordability and help households manage long-term treatment expenses. The revised MRPs are particularly significant because the reported reductions cover hundreds of brands and multiple anti-cancer formulations. The measure also reinforces the role of medicine-price regulation in improving transparency and preventing excessive trade margins. For patients, checking the revised MRP is important. Even when a price reduction has been announced, the exact saving depends on the particular medicine and formulation prescribed.
The NPPA has clarified that pharmacies, chemists and hospital pharmacies cannot charge more than the revised MRP applicable to the medicine. Consumers are advised to check the price printed on medicine packaging before making a purchase.
Patients and caregivers can also verify medicine prices through the Pharma Sahi Daam mobile application or the NPPA website. If a retailer or hospital pharmacy charges more than the applicable revised MRP, consumers can register a complaint through the Pharma Jan Samadhan portal or contact the NPPA helpline at 1800-111-255.
The government initiative follows a trade-margin rationalisation exercise intended to limit excessive margins in the sale of selected anti-cancer medicines. By regulating the permitted trade margin, the policy aims to bring down retail prices while improving transparency in medicine pricing.
However, the actual savings for individual patients will vary depending on the medicine, brand, formulation, prescribed treatment and previous purchase price. Consumers should verify the exact formulation and revised MRP rather than assume that every cancer medicine has received the same percentage reduction.
The implementation marks an important development in India's efforts to improve access to affordable cancer medicines. Its effectiveness will depend on compliance across manufacturers, distributors, pharmacies and hospitals.
